Acta Pharmaceutica Sinica B
药学报 B
第 13 卷,第 4 期,2023 年 4 月,页码 1616-1630
ORIGINAL ARTICLE 原文The E3 ubiquitin ligase NEDD4-1 protects against acetaminophen-induced liver injury by targeting VDAC1 for degradation
E3 泛素连接酶 NEDD4-1 通过靶向 VDAC1 降解来防止对乙酰氨基酚诱导的肝损伤
Graphical abstract 图形摘要
This study indicates that NEDD4-1 is a suppressor of APAP-induced liver injury and functions by regulating the degradation of voltage-dependent anion channel 1
本研究表明,NEDD4-1 是 APAP 诱导的肝损伤的抑制因子,通过调节电压依赖性阴离子通道 1 的降解而发挥作用
Key words 关键词
对乙酰氨基酚NEDD4-1VDAC1肝损伤肝毒性坏死线粒体损伤泛素化
1. Introduction 1. 引言
Acetaminophen (APAP), also called paracetamol, is a widely used analgesic that is safe at therapeutic doses1, 2, 3. However, APAP induces various degrees of liver damage when ingested at supratherapeutic doses or misused by at-risk individuals, and APAP overdose is currently the most frequent cause of drug-induced acute liver injury in many countries2,4,5. APAP-induced liver injury (AILI) accounts for 39% and 57% of acute liver failure cases in the USA and UK, respectively4,5.
对乙酰氨基酚 (APAP),也称为扑热息痛,是一种广泛使用的镇痛药,在治疗剂量下是安全的1、2、3。然而,当以超治疗剂量摄入或被高危人群滥用时,APAP 会诱发不同程度的肝损伤,而 APAP 过量是目前许多国家 2 4 5 药物诱发急性肝损伤的最常见原因。在美国和英国,APAP诱发的肝损伤(AILI)分别 4 占急性肝衰竭病例的39%和57 5 %。
The hepatotoxicity of APAP stems from its reactive metabolite, N-acetyl-p-benzoquinone imine (NAPQI)6,7. When APAP overdose occurs, excessive NAPQI generated by cytochrome p450 enzymes (CYPs, mainly CYP2E1) rapidly depletes glutathione (GSH) and binds to intracellular proteins, especially mitochondrial proteins6, 7, 8, resulting in mitochondrial damage, adenosine triphosphate (ATP) depletion, nuclear DNA damage and, ultimately, necrotic cell death in hepatocytes9, 10, 11. These pathological events are mutually promoted and thus lead to severe or even irreversible liver failure. Therefore, strategies for AILI therapy should target a key factor that is involved in prominent pathogenic pathways to ultimately inhibit multiple pathological features.
APAP的肝毒性源于其反应性代谢物N-乙酰基对苯醌亚胺(NAPQI)。 6 7 当APAP过量发生时,细胞色素p450酶(CYP,主要是CYP2E1)产生的过量NAPQI会迅速耗尽谷胱甘肽(GSH)并与细胞内蛋白结合,尤其是线粒体蛋白6,7,8,导致线粒体损伤,三磷酸腺苷(ATP)耗竭,核DNA损伤,最终导致肝细胞坏死细胞死亡9,10,11。这些病理事件是相互促进的,从而导致严重甚至不可逆的肝衰竭。因此,AILI治疗的策略应针对参与突出致病途径的关键因素,以最终抑制多种病理特征。
Ubiquitination is a posttranslational modification process that is accomplished via a sequential enzymatic catalytic cascade12, 13, 14 and requires an E3 ubiquitin ligase, which is the primary determinant of substrate specificity for ubiquitination15, 16, 17. By regulating intracellular protein fate, ubiquitination governs practically all aspects of cellular function and modulates cellular physiological and pathological processes12, 13, 14. Hence, it is constructive to discover key ubiquitination-related modulators implicated in the pathological mechanisms of AILI. Neural precursor cell expressed developmentally downregulated 4–1 (NEDD4-1), a member of the homologous to the E6-AP COOH terminus (HECT) E3 ubiquitin ligase family, is characterized by a C-terminal HECT domain, four WW repeats and an N-terminal C2 domain18. Studies have shown that NEDD4-1 targets many ubiquitination substrates via interactions with its WW domains and regulates diverse cellular physiological processes, including endocytosis, inflammasome activation, cell growth and proliferation, and autophagy19. Notably, aberrant expression of NEDD4-1 is associated with multiple human diseases20, 21, 22, such as endotoxic shock23, liver regeneration disorder24, ischemia/reperfusion injury21,25,26, and cancer22,27. However, to the best of our knowledge, no prior study has reported the role of NEDD4-1 in AILI.
泛素化是一种翻译后修饰过程,通过顺序酶催化级联12、13、14完成,需要E3泛素连接酶,这是泛素化底物特异性的主要决定因素15、16、17。通过调节细胞内蛋白质的命运,泛素化几乎控制细胞功能的所有方面,并调节细胞生理和病理过程12,13,14。因此,发现与AILI病理机制相关的关键泛素化相关调节剂是建设性的。神经前体细胞表达发育下调 4-1 (NEDD4-1),是 E6-AP COOH 末端 (HECT) E3 泛素连接酶家族同源的成员,其特征在于一个 C 端 HECT 结构域、四个 WW 重复序列和一个 N 端 C2 结构域 18 。研究表明,NEDD4-1 通过与其 WW 结构域的相互作用靶向许多泛素化底物,并调节多种细胞生理过程,包括内吞作用、炎症小体活化、细胞生长和增殖以及自噬 19 。值得注意的是,NEDD4-1 的异常表达与多种人类疾病有关20, 21, 22, 如内毒性休克 23 , 肝再生障碍 24 , 缺血/再灌注损伤 21 25 26 , 和癌症 22 27 。然而,据我们所知,之前没有研究报道 NEDD4-1 在 AILI 中的作用。
In the current study, we reveal that NEDD4-1 is a key suppressor of APAP-induced mitochondrial damage, necrosis and liver injury. Mechanistically, NEDD4-1 directly interacts with voltage-dependent anion channel 1 (VDAC1) and mediates its K48-linked polyubiquitination and subsequent degradation, thereby protecting against APAP-induced mitochondrial damage, necrosis and liver injury.
在目前的研究中,我们发现 NEDD4-1 是 APAP 诱导的线粒体损伤、坏死和肝损伤的关键抑制因子。从机制上讲,NEDD4-1 直接与电压依赖性阴离子通道 1 (VDAC1) 相互作用并介导其 K48 连接的多泛素化和随后的降解,从而防止 APAP 诱导的线粒体损伤、坏死和肝损伤。
2. Materials and methods 2.材料与方法
2.1. Animals and treatment
2.1. 动物和治疗
Experimental animal protocols were approved by the Ethics Committee for Animal Care and Use of Jilin University (permit number: SY202008007; Changchun, China). The animals were treated humanely according to Laboratory animal-the guidelines for ethical review of animal welfare (GB/T 35,892–2018, China). Wild-type (WT) C57BL/6 N mice were purchased from Cyagen Biosciences (Suzhou, China). Mice with the floxed Nedd4-1 alleles (Flox; on a C57BL/6 N background) were also purchased from Cyagen Biosciences. Hepatocyte-specific Nedd4-1 knockout (HepKO; on a C57BL/6 N background) mice were generated by mating Flox mice with albumin-Cre mice (Cyagen Biosciences). Although it is now increasingly recognized that crossing Flox mice with albumin-Cre mice will not generate pure hepatocyte specific knockout mice since albumin is expressed in bipotent fetal liver progenitor cells that give rise to both hepatocytes and biliary cells28, albumin-Cre mice is still widely used and acceptable for generating hepatocyte specific knockout mice today29, 30, 31. All experiments described in this report used male mice aged 4–8 weeks. Mice were housed in a temperature (23 ± 2 °C) and humidity (40 ± 5%) controlled specific pathogen-free facility with a 12 h/12 h dark/light photocycle. Food and water were provided ad libitum.
实验动物实验方案由吉林大学动物护理与使用伦理委员会批准(许可证号:SY202008007;长春,中国)。根据《实验动物-动物福利伦理审查指南》(GB/T 35,892–2018,中国)对动物进行人道对待。野生型(WT)C57BL/6 N小鼠购自Cyagen Biosciences(中国苏州)。具有floxed Nedd4-1等位基因(Flox;在C57BL / 6 N背景上)的小鼠也从Cyagen Biosciences购买。通过将Flox小鼠与白蛋白-Cre小鼠交配产生肝细胞特异性Nedd4-1敲除(HepKO;在C57BL / 6 N背景上)小鼠(Cyagen Biosciences)。尽管现在人们越来越认识到,将Flox小鼠与白蛋白-Cre小鼠杂交不会产生纯肝细胞特异性敲除小鼠,因为白蛋白在产生肝细胞和胆细胞 28 的双能胎儿肝祖细胞中表达,白蛋白-Cre小鼠今天仍然被广泛使用和接受用于产生肝细胞特异性敲除小鼠29, 30, 31.本报告中描述的所有实验都使用4-8周龄的雄性小鼠。将小鼠饲养在温度(23±2°C)和湿度(40±5%)控制的无特定病原体设施中,具有12小时/ 12小时的暗/光光循环。食物和水是随意提供的。
For modeling AILI mouse models, mice were fasted overnight to reduce hepatic GSH levels before APAP injection. APAP (IA0030; Solarbio, Beijing, China) was dissolved in warm saline (0.9% NaCl; 55 °C), cooled to 37 °C, and injected intraperitoneally at a dose of 300 or 600 mg/kg. Animals were sacrificed 6, 12, or 24 h after APAP administration. Liver and serum samples at each indicated time point were collected for further experiments.
为了模拟AILI小鼠模型,小鼠在APAP注射前禁食过夜以降低肝脏GSH水平。APAP (IA0030;Solarbio,Beijing,China)溶于温盐水(0.9%NaCl;55°C)中,冷却至37°C,并以300或600mg/kg的剂量腹膜内注射。在APAP给药后6、12或24小时处死动物。收集每个指定时间点的肝脏和血清样本以进行进一步实验。
2.2. Analysis of serum parameters
2.2. 血清参数分析
Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), lactate dehydrogenase (LDH) activities, and high mobility group box 1 (HMGB1) concentration were measured using the ALT activity assay kit (MAK052; Sigma–Aldrich, St. Louis, MO, USA), AST activity assay kit (MAK055; Sigma–Aldrich), LDH activity assay kit (MAK066; Sigma–Aldrich), and mouse HMGB1 ELISA kit (NBP2-62767; Novus Biologicals, Littleton, CO, USA) according to the manufacturer's protocols, respectively.
使用 ALT 活性测定试剂盒 (MAK052) 测定血清丙氨酸氨基转移酶 (ALT)、天冬氨酸氨基转移酶 (AST)、乳酸脱氢酶 (LDH) 活性和高迁移率组框 1 (HMGB1) 浓度;Sigma–Aldrich, St. Louis, MO, USA)、AST 活性测定试剂盒 (MAK055;Sigma-Aldrich)、LDH活性测定试剂盒(MAK066;Sigma-Aldrich)和小鼠HMGB1 ELISA试剂盒(NBP2-62767;Novus Biologicals,Littleton,CO,USA)分别根据制造商的协议。
2.3. Hematoxylin and eosin (H&E) and immunohistochemical (IHC) staining
2.3. 苏木精和伊红(H&E)和免疫组化(IHC)染色
H&E and IHC staining were performed in paraffin-embedded liver sections. Briefly, liver samples were fixed in 4% paraformaldehyde overnight, dehydrated, cleared, and embedded in paraffin. The waxes were sectioned serially at 3–5 μm thickness. After deparaffinization and rehydration, standard H&E staining was carried out to visualize the pattern in necrotic areas of the liver. The VDAC1 expression profiles in mice liver samples were determined by incubating the liver sections with anti-VDAC1 primary antibodies. Histological features were observed and captured under a light microscope (Olympus Corporation, Tokyo, Japan). The details of antibodies are listed in Supporting Information Table S1.
H&E和IHC染色在石蜡包埋的肝脏切片中进行。简而言之,将肝脏样品固定在4%多聚甲醛中过夜,脱水,澄清并包埋在石蜡中。蜡以 3-5 μm 的厚度连续切片。脱蜡和复液后,进行标准H&E染色以可视化肝脏坏死区域的模式。通过将肝切片与抗 VDAC1 一抗孵育来测定小鼠肝脏样品中的 VDAC1 表达谱。在光学显微镜下观察和捕获组织学特征(奥林巴斯公司,日本东京)。抗体的详细信息列在支持信息表 S1 中。
2.4. Protein extraction and western blotting
Total protein was extracted from liver tissue or cells, and prepared for Western blotting according to manufacturer's instructions (P0013K; Beyotime Institute of Biotechnology, Shanghai, China). Mitochondrial and cytosolic fractions used for Western blotting were isolated from fresh liver tissue or hepatocytes using a mitochondria isolation kit (MP-007; Invent Biotechnologies, Eden Prairie, MN, USA) according to manufacturer's instructions. Protein abundance of each molecular was determined by Western blotting as previously described32. The details of antibodies are listed in Table S1.
2.5. RNA extraction and quantitative real-time polymerase chain reaction
Protocol for quantitative real-time polymerase chain reaction was the same as described previously32,33. Briefly, total RNA was extracted using RNAiso Plus (D9108, TaKaRa Biotechnology, Dalian, China) according to manufacturer's instructions. Complementary DNA was reverse-transcribed from 1 μg total RNA using a reverse transcription kit (RR047A, TaKaRa Biotechnology). Relative mRNA expression of target genes was detected using the TB Green Premix Ex Taq II (RR82LR, TaKaRa Biotechnology) on the 7500 Real-Time PCR System (Applied Biosystems, Bedford, MA, USA). The relative expression of target genes was normalized to reference gene (Actb) using 2−ΔΔCT method34. Primer sequences are listed in Supporting Information Table S2.
2.6. Cell isolation, culture, and treatment
Mouse primary hepatocytes were isolated from six- to 8-week-old male mice (C57BL/6 N background) as previously described35,36, with modification. Briefly, mice were anesthetized and perfused in situ with D-HBSS (PB180322; Procell Life Science & Technology, Wuhan, China) containing 5 mmol/L EDTA and then HBSS (PB130824; Procell Life Science & Technology) containing 0.5 mg/mL collagenase type IV (17104019; Gibco, Grand Island, NY, USA) via the portal vein. The cell suspension was filtered through a 70-μm cell strainer (431,751; Corning, NY, USA) and centrifuged at 50 × g for 5 min at 4 °C. After that, the cell pellets were resuspended and mounted over a cushion of 25% Percoll (17089101; Cytiva Sweden AB, Uppsala, Sweden) to eliminate non-parenchymal cells. The obtained hepatocytes were washed with DMEM (SH30021.01; HyClone, Logan, UT, USA) and then cultured with William's E medium (PM151213; Procell Life Science & Technology) containing 10% fetal bovine serum (FBS; FB15015; Clark Bioscience, Richmond, VA, USA) in a 37 °C incubator with 5% CO2 and humidified atmosphere. Endothelial cells, cholangiocytes and stromal cells were isolated based on bilio-vascular tree isolation procedure as previously described37. In situ perfusion of the liver was performed as described above. The digested liver was acquired and placed in pre-chilled DMEM. Liver parenchyma was mechanically detached and discarded. The remaining bilio-vascular tree was minced and digested in DMEM containing 0.075 mg/mL collagenase P (11213865001; Roche, Indianapolis, IN, USA), 0.02 mg/mL DNase I (D8071; Solarbio, Beijing, China), 3% FBS, 1 mg/mL bovine serum albumin, 1% HEPES and 1% Penicillin–Streptomycin at 37 °C. The digested bilio-vascular fragments were collected on top of a 40-μm cell strainer (352340; Corning) and digested in 0.05% Trypsin–EDTA containing 0.02 mg/mL DNase I at 37 °C. Endothelial cells and cholangiocytes were isolated through a magnetic selection method using CD31 microbeads (130-097-418; Miltenyi Biotec, San Diego, CA, USA) and EpCAM microbeads (130-105-958; Miltenyi Biotec), respectively. Enriched stromal cell fraction was collected after excluding endothelial cells and cholangiocytes. 293 T cell lines were purchased from the Cell Bank of Type Cultural Collection of Chinese Academy of Sciences (Shanghai, China), and cultured in DMEM (SH40007.01; HyClone) supplemented with 10% FBS at a 37 °C incubator with 5% CO2.
To detect the effect of APAP on NEDD4-1 in vitro, primary hepatocytes were treated with different concentrations (0, 5, 10, or 20 mmol/L) of APAP for 12 h, or 10 mmol/L APAP for different times (0, 3, 6, or 12 h). To mimic APAP-induced hepatotoxicity in vitro, primary hepatocytes were treated with 10 mmol/L APAP for 12 h. To overexpress NEDD4-1 or knockdown VDAC1 in vitro, hepatocytes were infected with adenovirus expressing mouse Nedd4-1 gene sequence (Ad-NEDD4-1) or adenovirus expressing short hairpin RNA (shRNA) targeting mouse Vdac1 gene (Ad-shVDAC1) at a multiplicity of infection of 50 for 36–48 h, respectively. To inhibit the lysosomal degradation pathway of proteins, hepatocytes were treated with lysosome inhibitor chloroquine (CQ; 50 μmol/L) for 6 h before harvest. To inhibit the proteasomal degradation pathway of proteins, hepatocytes were treated with proteasome inhibitor MG132 (10 μmol/L) for 10 h before harvest. To inhibit c-Jun N-terminal kinase (JNK) signaling, hepatocytes were pretreated with 20 μmol/L SP600125 2 h before APAP treatment. For coimmunoprecipitation assays, 293 T cells were transfected with the indicated plasmids for 24–48 h using Lipofectamine 3000 (L3000015; Invitrogen, Carlsbad, CA, USA).
2.7. Immunofluorescence assay
For immunofluorescence, cells were fixed with 4% paraformaldehyde at room temperature for 15 min, washed twice with PBS, and then permeabilized with 0.1% Triton X-100 for 1 h. After washing with PBS twice, cells were incubated with primary antibodies diluted in PBS containing 5% bovine serum albumin overnight at 4 °C. Cells were then washed three times for 5 min with Tris-buffered saline–Tween 20, and incubated with corresponding fluorescent secondary antibodies. Subsequently, cells were washed twice with Tris-buffered saline–Tween 20, and then stained with DAPI. Cells were observed by a laser scanning confocal microscopy (Olympus FluoView 1200; Olympus Corporation). Fluorescence line profile and co-localization analyses were performed with Fiji software38. The details of antibodies are listed in Table S1.
2.8. RNA sequencing (RNA-seq) and data processing
For the RNA-seq analysis, total RNA was extracted from liver samples of APAP-treated Flox or APAP-treated HepKO mice. Libraries were constructed from total RNA and paired-end sequencing was performed on an Illumina Novaseq 6000 (Illumina, San Diego, CA, USA). Raw sequencing data were quality-controlled with Cutadapt and FastQC program. Reads were matched to reference genome sequences (mm10/GRCm38) using HISAT2 (version 2.1.0). Fragment per kilobase of transcript per million mapped reads mapped value was estimated by StringTie (version 1.3.4 d). Differential gene expression analysis was performed using DEseq2 (version 1.2.10) according to the following two criteria: (1) folding change ≥2 and (2) false discovery rate <0.05. The hierarchical clustering analysis was performed to analyze global sample distribution profiles by constructing a clustering tree based on data from RNA-seq by R function hclust. Gene set enrichment analysis (GSEA) was performed using the R package ReactomePA (version 1.30.0) with default parameters. Gene sets with P values < 0.05 were considered statistically significant. RNA-seq data generated in this study have been deposited in the Gene Expression Omnibus public database under accession number GSE199353.
2.9. Measurement of viable and dead cells
Calcein-AM/propidium iodide (PI) double staining kit (40747ES76; Yeasen Biotechnology, Shanghai, China) was utilized for simultaneous fluorescence staining of viable and dead cells. This kit contains Calcein-AM and PI solutions, which stain viable and dead cells, respectively. After treatment as indicated in results, cells were stained according to manufacturer's instruction. Firstly, washing cells with 1 × assay buffer three times to remove residual esterase activity. After that, cells were incubated with the working solution (2 μmol/L Calcein-AM and 4.5 μmol/L PI in 1 × assay buffer) for 20 min at 37 °C, protected from light. Following incubation, cells were washed gently with 1 × assay buffer three times, and then visualized by a laser scanning confocal microscopy (Olympus FluoView 1200).
2.10. Adeno-associated virus 8 (AAV8) injection
The AAV8 delivery system was constructed by Vigene Bioscience (Jinan, China). For NEDD4-1 overexpression, mice were injected with AAV8-TBG (a genetic delivery system containing hepatocyte-specific promoter TBG and exhibiting high specificity and transfection efficiency in hepatocytes) carrying the full length mouse Nedd4-1 gene sequence (AAV8-NEDD4-1). For VDAC1 knockdown, mice were injected with AAV8 vectors bearing shRNA targeting mouse Vdac1 gene (AAV8-shVDAC1). Mice were injected in the lateral tail vein with 200 μL of virus containing 2.5 × 1011 AAV8 vector genomes. The shVdac1 sequences are listed in Supporting Information Table S3.
2.11. Transmission electron microscopy
Primary hepatocytes were fixed in 2.5% glutaraldehyde overnight at room temperature. Then, cells were post-fixed in potassium ferrocyanide–osmium tetroxide for 1 h and dehydrated in a bath with increasing concentrations of ethanol. After embedding and slicing, cells were staining with uranyl acetate and lead citrate. Sections were observed under a H-7650 transmission electron microscope (Hitachi Limited, Tokyo, Japan).
2.12. Detection of liver reactive oxygen species (ROS) content and ATP content
The content of ROS in liver tissue was measured using the tissue ROS test kit (HR8821; BioRab, Beijing, China) according to manufacturer's instructions and normalized to protein concentration. Briefly, fresh liver tissue was homogenized in cold buffer and centrifuged (100 × g) for 5 min at 4 °C. The supernatant was used to analyze ROS content. Add 200 μL of supernatant and 2 μL of dihydroethidium probe to a 96-well plate, and mix them well. Plate was incubated at 37 °C for 30 min in dark, and then read on a Molecular Devices SpectraMax Gemini EM (Molecular Devices, Sunnyvale, CA, USA) at λexc = 510 nm and λemi = 610 nm.
The content of ATP in liver tissue was measured using the ATP colorimetric/fluorometric assay kit (K354-100; BioVision, Milpitas, CA, USA) according to manufacturer's instructions and normalized to protein concentration.
2.13. Seahorse assay
Oxygen consumption rate (OCR) was measured using the Seahorse XFe 24 Analyzer (Agilent Technologies, Santa Clara, CA, USA). 3 × 104 hepatocytes per well were plated as a monolayer culture in Seahorse cell plates. To perform the mitochondrial stress test, 2 μmol/L oligomycin, 1.5 μmol/L FCCP, and 1 μmol/L antimycin A + 1 μmol/L rotenone were added as indicated.
2.14. Measurement of intracellular mitochondrial membrane potential and mitochondrial ROS (mtROS)
Intracellular mitochondrial membrane potential and mtROS production were visualized using the JC-1 mitochondrial membrane potential assay kit (C0008; Applygen Technologies, Beijing, China) or the MitoSOX Red Mitochondrial Superoxide Indicator (40778ES50; Yeasen Biotechnology) according to manufacturer's instruction, respectively. To measure intracellular mitochondrial membrane potential, cells were incubated with 10 μg/mL of JC-1 working solution for 20 min at 37 °C, protected from light. To measure intracellular mtROS, cells were incubated with 4.5 μmol/L of MitoSOX working solution for 10 min at 37 °C, protected from light. After incubation, cells were washed gently three times with warm buffer, and then visualized by a laser scanning confocal microscopy (Olympus FluoView 1200).
2.15. VDAC1 cross-linking assay
To detect the oligomeric forms of VDAC1, chemical cross-linking of cells was performed as described previously39,40. Briefly, hepatocytes were washed twice with PBS, harvested, and incubated with 0.5 mmol/L EGS (21565, ThermoScientific, Waltham, MA, USA) in PBS (pH 7.4) at 30 °C for 20 min. The pellet was lysed in NP-40 lysis buffer by sonication on ice. Samples were subjected to SDS-PAGE and immunoblotting using anti-VDAC1 antibody.
2.16. Plasmid construction
WT and truncated fragments of mouse Nedd4-1 were amplified from mouse complementary DNA and cloned into the pcDNA3.1-HA vector. WT fragments of mouse Vdac1 were amplified from mouse complementary DNA and cloned into the pEnCMV-3 × Flag vector. Mutant fragment of mouse NEDD4-1 (NEDD4-1C854S) and PPTY deletion fragment of mouse VDAC1 (VDAC1△PPTY) were generated using Q5 Site-Directed Mutagenesis Kit (E0554S; New England BioLabs, Ipswich, MA, USA). Each construction was verified by sequencing (Comate Bioscience, Changchun, China).
2.17. Coimmunoprecipitation (Co-IP) assay
293 T cells were lysed in ice-cold NP40 lysis buffer supplemented with a protease inhibitor cocktail, and centrifuged (12,000 × g) at 4 °C for 10 min. The cell lysates were used for immunoprecipitation with Pierce Crosslink Immunoprecipitation Kit (26,147, Thermo Scientific), anti-Flag M2 affinity gel (A2220, Sigma–Aldrich), or anti-HA affinity gel (E6779, Sigma–Aldrich). The obtained beads were washed five times with lysis buffer, and the immunoprecipitates were obtained by boiling in 2 × loading buffer at 95 °C for 5 min, or eluted by 100 μg/mL HA peptide (I2149; Sigma–Aldrich). Finally, the immunoprecipitates and whole cell lysates were subjected to immunoblotting using the indicated primary antibodies and corresponding secondary antibodies. The details of antibodies are listed in Table S1.
2.18. Measurement of cell viability
Cell viability was detected using cell counting kit-8 (C0038; Beyotime Institute of Biotechnology) according to manufacturer's instructions.
2.19. Statistical analysis
Data were generated from multiple repeats of different biological experiments and were analyzed using the appropriate statistical analysis methods. Statistical significance of Kaplan–Meier survival curves was analyzed by log-rank test. The correlation between two parameters was analyzed by the Pearson correlation analysis. Statistical significance of the rest of data was calculated using the two-tailed unpaired Student t test, or ANOVA with Bonferroni correction. Results are presented as the mean ± standard error of mean (SEM). P value < 0.05 is considered statistically significant. Statistics were performed using GraphPad Prism software (Version 6; GraphPad Software Inc., La Jolla, CA, USA) and Statistical Package for the Social Sciences (SPSS) software (Version 19.0; SPSS Incorporated, Chicago, IL, USA).
3. Results
3.1. Hepatocyte NEDD4-1 expression is dramatically downregulated in AILI and negatively correlates with liver injury severity
To explore the potential role of NEDD4-1 in AILI, six- to 8-week-old male C57BL/6 N mice were administered either a nonlethal (300 mg/kg) or lethal (600 mg/kg) dose of APAP over different durations by intraperitoneal injection. Administration of APAP resulted in hepatic injury, as indicated by highly increased serum ALT and AST activities (Supporting Information Fig. S1A and S1B). Typical features of liver injury and centrilobular hepatocellular necrosis were also observed by H&E staining in APAP-treated mice (Fig. S1C).
The protein (Fig. 1A and B) and mRNA (Fig. 1C) abundances of NEDD4-1 were markedly reduced in time- and dose-dependent manners in the livers of APAP-challenged mice. In addition, hepatic Nedd4-1 mRNA expression was negatively correlated with serum ALT and AST activities, as determined by Pearson correlation analysis (Fig. 1D and E). Due to the cellular heterogeneity of liver tissue, we analyzed a publicly available single-cell RNA-seq dataset derived from normal human livers (GSE192742; https://www.livercellatlas.org/index.php)41 and found that NEDD4-1 was predominantly expressed in hepatocytes and, to a lesser extent, in cholangiocytes, endothelial cells, and stromal cells (Fig. S1D). These four types of cells were thus isolated from the livers of mice administered saline or APAP. The NEDD4-1 protein abundance was lower in hepatocytes but not in other cell types from APAP-treated mice (Fig. S1E), suggesting that APAP overdose selectively decreases the abundance of NEDD4-1 in hepatocytes. Similarly, in vitro, APAP treatment downregulated NEDD4-1 expression in WT hepatocytes in time- and dose-dependent manners (Fig. 1F and G; Fig. S1F). The decrease of NEDD4-1 abundance in APAP-treated mouse primary hepatocytes was also confirmed by immunofluorescence analyses (Fig. 1H). These results suggest a potential regulatory role of NEDD4-1 in APAP-induced hepatotoxicity.
3.2. Hepatocyte NEDD4-1 deficiency exacerbates APAP-induced liver injury and necrosis
To understand the role of NEDD4-1 in the liver and the mechanism by which its downregulation contributes to AILI pathogenesis, we generated mice with hepatocyte-specific Nedd4-1 knockout (hereafter referred to as HepKO mice) (Supporting Information Fig. S2A). Western blot analysis confirmed the specific knockout of NEDD4-1 in the livers of HepKO mice (Fig. S2B). Unchallenged HepKO mice were healthy and fertile without noticeable gross phenotypes and demonstrated no significant differences in body weight (Fig. S2C) and the liver weight/body weight ratio (Fig. S2D) compared with those of their Flox counterparts. However, under challenge with 300 mg/kg APAP, NEDD4-1 loss led to more severe liver injury, as indicated by the higher serum ALT (Fig. 2A), AST (Fig. 2B), and LDH (Fig. 2C) activities. In addition, hepatocyte NEDD4-1 deficiency evidently exacerbated the APAP-induced increase in the serum level of HMGB1 (Fig. 2D), a nuclear protein released extracellularly from necrotic cells42, 43, 44. H&E staining (Fig. 2E) and evaluation of gross liver appearance (Fig. S2E) further confirmed the enhancement of APAP-induced liver injury and necrosis in APAP-treated HepKO mice. In particular, HepKO mice had a much lower survival rate than Flox mice after treatment with a lethal dose (600 mg/kg) of APAP (Fig. 2F). In addition, identical protein abundances of CYP2E1 (Fig. S2F) and GSH levels (Fig. S2G) were observed in the livers of APAP-treated Flox and HepKO mice, indicating unaffected APAP metabolism. Taken together, these results indicate that hepatocyte-specific NEDD4-1 deficiency exacerbates APAP-induced liver injury and necrosis.
To gain better insight into the pathological alterations initiated by hepatocyte NEDD4-1 deficiency in the AILI setting, we performed RNA-seq using liver samples from APAP-treated Flox and HepKO mice. Unsupervised hierarchical clustering showed that liver samples from these two groups were clearly separated (Supporting Information Fig. S3A), with 1201 upregulated and 736 downregulated genes (Fig. 2G, Supporting Information Table S4) in the APAP-treated HepKO group. GSEA revealed that the upregulated genes were associated with the chemokine, inflammasome, DNA damage, tumor necrosis factor signaling, and cell death pathways (Fig. 2H, red; Fig. S3B). In addition, mitochondrial function-related genes associated with fatty acid oxidation and mitochondrial translation were downregulated (Fig. 2H, gray; Fig. S3B). These RNA-seq data further demonstrate the negative effects of NEDD4-1 deficiency on AILI.
For further in vitro experiments, hepatocytes were isolated from HepKO and Flox mice (Supporting Information Fig. S4) and were then exposed to APAP. NEDD4-1 deletion in hepatocytes markedly exacerbated APAP-induced hepatocyte death, as determined by Calcein-AM/PI double staining (Fig. 2I), an LDH release assay (Fig. 2J) and measurement of the HMGB1 concentration in the culture medium (Fig. 2K). Taken together, these in vivo and in vitro results reveal that loss of hepatocyte NEDD4-1 exacerbates APAP-induced liver injury and necrosis.
3.3. Overexpression of hepatocyte NEDD4-1 alleviates APAP-induced liver injury and necrosis
To further confirm the function of hepatocyte NEDD4-1 in AILI, we generated mice with hepatocyte NEDD4-1 overexpression using AAV8 delivering hepatocyte-specific promoter TBG and full-length Nedd4-1 gene sequence (AAV8-NEDD4-1), and examined their response to APAP treatment (Supporting Information Fig. S5A). Western blot analysis confirmed the overexpression of NEDD4-1 in the livers of AAV8-NEDD4-1-injected mice (Fig. S5B). The similar levels of CYP2E1 protein abundance (Fig. S5C) and GSH depletion (Fig. S5D) indicated that APAP metabolism was not influenced by AAV8-NEDD4-1 injection. Compared to AAV8-Control-injected mice, AAV8-NEDD4-1-injected mice showed alleviation of liver injury and necrosis in response to APAP challenge, as indicated by the decreased necrotic area (Fig. 3A); decreased serum ALT (Fig. 3B), AST (Fig. 3C) and LDH (Fig. 3D) activities; and reduced serum HMGB1 level (Fig. 3E). Moreover, AAV8-mediated hepatocyte NEDD4-1 overexpression was sufficient to increase the mouse survival rate upon administration of a lethal dose (600 mg/kg) of APAP (Fig. 3F).
For in vitro experiments, primary hepatocytes obtained from WT mice were transfected with adenovirus containing the NEDD4-1 plasmid or control vector (Fig. S5E) and then exposed to APAP. Consistent with the in vivo results, APAP-induced cell death was also alleviated by NEDD4-1 overexpression in primary hepatocytes, as indicated by the decreased cell death rate (PI positive cells %; Fig. 3G), level of LDH release (Fig. 3H), and concentration of HMGB1 in the culture medium (Fig. 3I). Based on the combined in vivo and in vitro results, we conclude that hepatocyte NEDD4-1 overexpression ameliorates APAP-induced liver injury and necrosis.
3.4. NEDD4-1 mediates APAP-induced hepatocyte mitochondrial damage
Our RNA-seq data demonstrate an enhanced defect in mitochondrial function in APAP-treated HepKO mice. Therefore, we investigated the influence of NEDD4-1 on mitochondrial homeostasis in the setting of AILI by determining the ATP and ROS contents, mitochondrial membrane potential, mitochondrial membrane permeabilization, etc. APAP-induced hepatic ATP depletion (Fig. 4A), ROS overproduction (Fig. 4B), and cytosolic leakage of mitochondrial intermembrane proteins (apoptosis-inducing factor [AIF], endonuclease G [Endo G] and cytochrome c [Cyt C]; Fig. 4C) were aggravated by hepatocyte NEDD4-1 knockout in vivo, indicating that hepatocyte NEDD4-1 deficiency exacerbated APAP-induced mitochondrial damage. Conversely, overexpression of hepatocyte NEDD4-1 by AAV8-NEDD4-1 injection caused a beneficial improvement in APAP-induced mitochondrial damage (Supporting Information Fig. S6A–S6C).
In vitro, transmission electron microscopy revealed mitochondrial swelling and damage in APAP-treated Flox hepatocytes, which was even worse in APAP-treated HepKO hepatocytes (Fig. 4D). In addition, upon APAP treatment, HepKO hepatocytes displayed greater increases in the cytosolic release of mitochondrial intermembrane proteins (AIF, Endo G and Cyt C) than Flox hepatocytes (Fig. 4E). OCR measurements obtained by a Seahorse assay demonstrated that the impairment of basal respiration, ATP production and maximal respiration induced by APAP exposure were further aggravated by hepatocyte NEDD4-1 ablation, revealing a more severe defect in mitochondrial function (Fig. 4F). JC-1 staining, which is used to visualize the mitochondrial membrane potential by detecting fluorescence, indicated that NEDD4-1 ablation in primary hepatocytes aggravated the APAP-induced collapse of the mitochondrial membrane potential (Fig. 4G). Meanwhile, MitoSOX staining was performed to evaluate mtROS production in vitro and showed that knockout of NEDD4-1 in hepatocytes increased APAP-induced overproduction of mtROS (Fig. 4H). In contrast, transfection of NEDD4-1 adenovirus into WT primary hepatocytes significantly mitigated APAP-induced mitochondrial damage, as evidenced by the Seahorse assay (Fig. S6D), JC-1 staining (Fig. S6E), and MitoSOX staining (Fig. S6F).
In summary, these gain- and loss-of-function studies in vivo and in vitro show that hepatocyte NEDD4-1 at least partially mediates APAP-induced hepatocyte mitochondrial damage.
3.5. Knockdown of VDAC1 mitigates the enhanced AILI events caused by hepatocyte NEDD4-1 deficiency
The striking effect of NEDD4-1 on mitochondrial intermembrane protein leakage in the setting of AILI prompted us to investigate the influence of NEDD4-1 on proteins related to mitochondrial membrane permeabilization. Intriguingly, under APAP treatment, hepatocyte NEDD4-1 ablation increased the mitochondrial translocation of phosphorylated JNK (P-JNK) and the protein abundance of mitochondrial VDAC1, but had a negligible influence on the protein abundance of mitochondrial bcl-2-associated X (Bax) and cyclophilin D (CYPD) (Fig. 5A). In contrast, NEDD4-1 overexpression resulted in the opposite trends in the protein levels of mitochondrial P-JNK and VDAC1 in APAP-treated primary hepatocytes (Supporting Information Fig. S7A).
Since NEDD4-1 markedly influenced the VDAC1 protein abundance in the setting of AILI, we sought to determine whether VDAC1 participates in the regulation of NEDD4-1 in AILI pathogenesis. First, the expression profile of hepatic VDAC1 in the setting of AILI was determined. Results showed that the VDAC1 protein abundance was markedly increased in the livers of APAP-challenged mice (Fig. 5B and C) and in APAP-treated primary hepatocytes (Fig. S7B), although VDAC1 mRNA expression did not differ significantly (Fig. 5D), suggesting that the increase in the VDAC1 protein abundance upon APAP treatment was not due to changes in transcription.
To further elucidate the role of VDAC1 in NEDD4-1-regulated AILI, VDAC1 was silenced in Flox and HepKO mice via tail vein injection of AAV8-shVDAC1, and the mice were then exposed to APAP (Supporting Information Fig. S8A). The silencing efficiency of AAV8-shVDAC1 in HepKO mice was validated by Western blotting (Fig. S8B). AAV8-shVDAC1 injection did not affect the CYP2E1 protein abundance (Fig. S8C) and GSH depletion (Fig. S8D), indicating unaffected APAP metabolism. Nevertheless, AAV8-shVDAC1 injection significantly alleviated liver injury and necrosis both in APAP-treated Flox mice and in APAP-treated HepKO mice compared with their corresponding controls, as indicated by H&E staining (Fig. 5E); serum ALT (Fig. 5F), AST (Fig. 5G), LDH activities (Fig. 5H); HMGB1 levels (Fig. 5I); and gross liver appearance (Fig. S8E). Consistent with these findings, the reduction in the survival rate was ameliorated by VDAC1 knockdown (Fig. 5J). Moreover, hepatic mitochondrial damage was alleviated by injection of AAV8-shVDAC1 (Fig. 5K and L). Notably, the mitochondrial translocation of P-JNK induced by NEDD4-1 deficiency under APAP exposure was reduced by VDAC1 knockdown, suggesting that VDAC1 may function cooperatively with JNK (Fig. 5M). Collectively, these results show that knockdown of VDAC1 effectively alleviates APAP-induced mitochondrial damage, liver injury and necrosis. More importantly, the enhanced AILI events caused by hepatocyte NEDD4-1 deficiency were also weakened by VDAC1 knockdown in vivo. These in vivo phenomena were also evaluated in vitro in HepKO hepatocytes treated with APAP and Ad-shVDAC1 (Fig. S8F). Under APAP exposure, the cell death rate (PI positive cells %; Fig. 6A), LDH release (Fig. 6B) and HMGB1 concentration in the culture medium (Fig. 6C) were lower in the Ad-shVDAC1 group than in the Ad-shControl group. Furthermore, mitochondrial damage enhanced by hepatocyte NEDD4-1 knockout was also mitigated by VDAC1 knockdown under APAP treatment in vitro, as determined by a Seahorse assay (Fig. 6D), JC-1 staining (Fig. 6E), and MitoSOX staining (Fig. 6F). These data indicate that knockdown of VDAC1 protects against the enhancement of APAP-induced pathological events resulting from hepatocyte NEDD4-1 deficiency in vitro.
As a recent study revealed that VDAC1 oligomerization mediates APAP toxicity45, we further investigated whether NEDD4-1 affects VDAC1 oligomerization in APAP toxicity. In vitro experiments showed that NEDD4-1 knockout promoted APAP-induced VDAC1 oligomerization (Supporting Information Fig. S9A), which was reduced by NEDD4-1 overexpression (Fig. S9B). These results indicate that NEDD4-1 regulates VDAC1 oligomerization in APAP toxicity.
3.6. Identification of VDAC1 as a functional ubiquitination substrate of NEDD4-1
Since the increase in the VDAC1 protein abundance upon APAP treatment was not due to transcriptional changes, we rationally deduced that in the setting of AILI, VDAC1 is regulated through proteasomal degradation via the E3 ubiquitin ligase NEDD4-1. As expected, NEDD4-1 overexpression significantly decreased the protein abundance of VDAC1, and this effect was blocked by the proteasome inhibitor MG132 but not by the lysosome inhibitor CQ, emphasizing that NEDD4-1 regulates the proteasomal degradation of VDAC1 (Fig. 7A).
The interaction of exogenous NEDD4-1 with VDAC1 was demonstrated by reciprocal Co-IP (Fig. 7B and C). Consistently, intracellular colocalization of endogenous NEDD4-1 and VDAC1 was further observed in primary hepatocytes via an immunofluorescence colocalization assay (Fig. 7D). Subsequently, molecular mapping assays using WT and truncated fragments of NEDD4-1 revealed that the WW domain of NEDD4-1 is responsible for its interaction with VDAC1 (Fig. 7E). Moreover, missing PPTY motif in VDAC1 abolished its interaction with NEDD4-1 (Fig. 7F). Taken together, these results clarify that NEDD4-1 binds to the PPTY motif of VDAC1 through its WW domain.
Next, we investigated whether NEDD4-1 promotes the ubiquitination of VDAC1. As shown in the ubiquitination assays, NEDD4-1 significantly facilitated the ubiquitination of VDAC1 (Fig. 7G and H), but the NEDD4-1C854S mutant lacking ubiquitin ligase activity did not (Fig. 7H). These results indicate that NEDD4-1-catalyzed ubiquitination of VDAC1 depends on its E3 ubiquitin ligase activity. Screening for potential lysine ubiquitination types revealed that both WT and K48O (ubiquitin with the intact Lys48 residue only) ubiquitin but not K6O, K11O, K27O, K33O, or K63O (Fig. 7I) could be linked to VDAC1 by NEDD4-1. Moreover, NEDD4-1 failed to link K48R ubiquitin (ubiquitin with mutation of Lys48) to VDAC1 (Fig. 7J). Investigation using a K48 linkage-specific anti-ubiquitin antibody further confirmed that NEDD4-1 facilitated K48-linked ubiquitination of VDAC1 (Fig. 7K). In summary, the present data indicate that NEDD4-1 directly interacts with VDAC1 and predominantly promotes K48-linked ubiquitination of VDAC1, eventually resulting in its degradation.
Accordingly, we propose a signaling mechanism in which VDAC1 is targeted as a degradation substrate of NEDD4-1 to mediate hepatocyte mitochondrial damage and necrosis during AILI (Fig. 8).
4. Discussion
Hepatotoxicity limits the clinical utility of APAP, although it remains the most ubiquitous over-the-counter antipyretic and analgesic worldwide5. APAP hepatotoxicity accounts for several fold more deaths related to acute liver failure than hepatotoxicity from all other prescription drugs combined3. However, there is currently no standard antidote to treat AILI except for N-acetylcysteine, which has certain limitations. Therefore, exploring the mechanisms by which APAP causes toxicity is essential to combat AILI with appropriate therapies. Here, we identified NEDD4-1 as a new and robust suppressor of AILI that functions to maintain hepatocyte mitochondrial homeostasis and protect against hepatic necrosis. Furthermore, VDAC1 was identified as a degradation substrate protein that mediates the downstream protective effects of NEDD4-1 against AILI. Considering these results, targeting the NEDD4-1–VDAC1 axis could be a feasible therapeutic strategy for AILI.
The E3 ubiquitin ligase NEDD4-1 has attracted extensive attention in recent decades for its vital role in regulating a diverse range of physiological processes and human diseases19, 20, 21, 22. Accumulating evidence has validated the protective effect of NEDD4-1 against tissue injury, such as hepatic and cardiac ischemia/reperfusion injury21,25,26. However, the role of NEDD4-1 in regulating drug-induced liver injury has not been described previously. Here, we found that hepatic NEDD4-1 expression was dramatically downregulated in AILI. Notably, HepKO mice showed higher mortality and more severe liver injury upon APAP overdose, while mice overexpressing NEDD4-1 exhibited alleviation of the response to APAP exposure, identifying NEDD4-1 as exerting protective effects against AILI. In addition, this conclusion was also supported by our in vitro findings.
AILI has a complex pathogenesis that involves multiple pathogenic events. The initiating event begins with the generation of NAPQI7,8,46, which then binds covalently to proteins, especially mitochondrial proteins. Widespread covalent binding results in cellular oxidative stress, mitochondrial dysfunction, DNA fragmentation, etc., culminating in necrosis and liver injury11,47,48. In this study, the RNA-seq data suggest that NEDD4-1 deficiency is implicated in multiple pathogenic pathways (oxidative stress, mitochondrial dysfunction, DNA damage and cell death) during AILI progression, all of which are closely related to mitochondria—the primary intracellular organelle targeted by APAP49. In particular, our loss- and gain-of-function experiments further demonstrated that NEDD4-1 at least partially mediates APAP-induced hepatocyte mitochondrial damage and necrosis. Therefore, mitochondrial damage is a critical pathological event in NEDD4-1 deficiency-mediated exacerbation of APAP hepatotoxicity.
The mitochondrial outer membrane is a functional barrier that physically separates mitochondria from the cytosol and orchestrates mitochondrial homeostasis50. VDAC1 is the most abundant gatekeeper in the mitochondrial outer membrane and forms pores that control the exchange of metabolites, nucleotides, ions, and small molecules between mitochondria and the cytosol51, 52, 53. Genetic alteration, abnormal expression, translocation, oligomerization and ubiquitination of VDAC1 regulate various cellular pathological processes, such as mitochondrial outer membrane permeabilization, mitochondrial DNA release, mitochondrial intermembrane protein release, mtROS production, and cell death52,54, 55, 56. All of these pathological processes have been validated to be major players in the pathogenesis of AILI, foreshadowing VDAC1 may participate in AILI progression. Indeed, our results provided evidence for the elevation of VDAC1 abundance as a result of AILI, which was supported by mitochondrial proteomic data57. It is noteworthy that VDAC is sometimes used as a mitochondrial reference protein. Nevertheless, our findings and those of other functional studies58, 59, 60, 61, 62 of VDAC1 suggested that the usage of VDAC as a mitochondrial reference protein should be exercised cautiously or validated in different contexts. Here, our subsequent experiments show that VDAC1 participates in AILI progression and that its abnormal accumulation is at least partially responsible for NEDD4-1 deficiency-mediated exacerbation of AILI. Specifically, in our study, VDAC1 knockdown significantly alleviated mitochondrial damage, necrosis and liver injury, which is most likely achieved through decreasing VDAC1 oligomerization as a recent study ascertained45. Mechanistically, we demonstrate that NEDD4-1 binds to the PPTY motif of VDAC1 through its WW domain, subsequently catalyzing K48-linked ubiquitination of VDAC1 and ultimately resulting in VDAC1 degradation. A recent study concerning drug resistance in melanoma cells during cancer therapy further supported the idea that VDAC1 is a degradation substrate of NEDD4-158. Taken together, our data indicate that targeting VDAC1 for degradation is the primary cellular mechanism by which NEDD4-1 performs a beneficial function in AILI.
Among the complex molecular networks coordinating APAP hepatotoxicity, JNK is a star molecule due to its comprehensive regulation of mitochondrial homeostasis. Activation and mitochondrial translocation are the prerequisites for JNK to exert its detrimental effects on AILI progression (Supporting Information Fig. S10)63, 64, 65, 66. Our study showed that ablation of hepatocyte NEDD4-1 enhanced the APAP-induced mitochondrial translocation of activated JNK, which was reduced by silencing of VDAC1. Convincing evidence indicates that VDAC1 mediates the cytosolic transport of superoxide anion and peroxynitrite67, whose presence in the cytosol enables the activation of JNK, ultimately amplifying mitochondrial dysfunction68. Thus, JNK may act as one of the executors responding to NEDD4-1–VDAC1 axis in the setting of AILI. However, further research on the exact regulatory mechanism linking the NEDD4-1–VDAC1 axis and JNK translocation is required.
5. Conclusions
Overall, the present study identifies that by facilitating ubiquitination-mediated degradation of VDAC1 in hepatocytes, NEDD4-1 attenuates AILI (Fig. 8). This fact makes NEDD4-1–VDAC1 axis a promising target for AILI therapy. Our collective findings provide further insights into AILI progression and offer new possibilities for therapies targeting this disease and its related pathologies.
Acknowledgments
This work was supported by the National Natural Science Foundation of China (Beijing, China; Grant Nos. 32022084 and 32172927).
Author contributions
Yiwei Zhu: conceptualization, validation, formal analysis, investigation, visualization, and writing-original draft; Lin Lei: conceptualization, formal analysis, investigation, and writing-review and editing; Xinghui Wang, Linfang Chen: validation, investigation, and writing-review and editing; Wei Li, Jinxia Li, Chenchen Zhao: investigation, and writing-review and editing; Xiliang Du, Yuxiang Song, Wenwen Gao: writing-review and editing; Guowen Liu: resources, and writing-review and editing; Xinwei Li: conceptualization, resources, writing-review and editing, supervision, project administration, and funding acquisition.
Conflicts of interest
The authors declare no conflicts of interest.
Appendix A. Supplementary data
The following are the Supplementary data to this article:
References
- 1Acute liver failureClin Liver Dis, 16 (2020), pp. 45-55
- 2Recommendations for the use of the acetaminophen hepatotoxicity model for mechanistic studies and how to avoid common pitfallsActa Pharm Sin B, 11 (2021), pp. 3740-3755
- 3Acetaminophen (APAP) hepatotoxicity—isn’t it time for APAP to go away?.J Hepatol, 67 (2017), pp. 1324-1331
- 4Acute liver failureLancet, 376 (2010), pp. 190-201
- 5Acute liver failureLancet, 394 (2019), pp. 869-881
- 6Metabolism and disposition of acetaminophen: recent advances in relation to hepatotoxicity and diagnosisPharm Res (N Y), 30 (2013), pp. 2174-2187
- 7N-Acetyl-p-benzoquinone imine: a cytochrome P-450-mediated oxidation product of acetaminophenProc Natl Acad Sci U S A, 81 (1984), pp. 1327-1331
- 8Acetaminophen-induced liver injury in rats and mice: comparison of protein adducts, mitochondrial dysfunction, and oxidative stress in the mechanism of toxicityToxicol Appl Pharmacol, 264 (2012), pp. 387-394
- 9Acetaminophen hepatotoxicity: an updated reviewArch Toxicol, 89 (2015), pp. 193-199
- 10Oxidant stress, mitochondria, and cell death mechanisms in drug-induced liver injury: lessons learned from acetaminophen hepatotoxicityDrug Metab Rev, 44 (2012), pp. 88-106
- 11Mechanisms of acetaminophen-induced liver injury and its implications for therapeutic interventionsRedox Biol, 17 (2018), pp. 274-283
- 12The ubiquitin systemAnnu Rev Biochem, 67 (1998), pp. 425-479
- 13Ubiquitylation and cell signalingEMBO J, 24 (2005), pp. 3353-3359
- 14Ubiquitin modificationsCell Res, 26 (2016), pp. 399-422
- 15New insights into ubiquitin E3 ligase mechanismNat Struct Mol Biol, 21 (2014), pp. 301-307
- 16Ubiquitin ligases: structure, function, and regulationAnnu Rev Biochem, 86 (2017), pp. 129-157
- 17Developing small-molecule inhibitors of HECT-type ubiquitin ligases for therapeutic applications: challenges and opportunitiesChembiochem, 19 (2018), pp. 2123-2135
- 18Physiological functions of the HECT family of ubiquitin ligasesNat Rev Mol Cell Biol, 10 (2009), pp. 398-409
- 19The many substrates and functions of NEDD4-1Cell Death Dis, 10 (2019), p. 904
- 20An outlined review for the role of Nedd4-1 and Nedd4-2 in lung disordersBiomed Pharmacother, 125 (2020), Article 109983
- 21E3 ubiquitin ligase NEDD4 family regulatory network in cardiovascular diseaseInt J Biol Sci, 16 (2020), pp. 2727-2740
- 22Molecular functions of NEDD4 E3 ubiquitin ligases in cancerBiochim Biophys Acta, 1856 (2015), pp. 91-106
- 23E3 ubiquitin ligase Nedd4 is a key negative regulator for non-canonical inflammasome activationCell Death Differ, 26 (2019), pp. 2386-2399
- 24Large-scale quantitative proteomics identifies the ubiquitin ligase Nedd4-1 as an essential regulator of liver regenerationDev Cell, 42 (2017), pp. 616-625
- 25TNFAIP3 interacting protein 3 is an activator of Hippo-YAP signaling protecting against hepatic ischemia/reperfusion injuryHepatology, 74 (2021), pp. 2133-2153
- 26NEDD4-1 protects against ischaemia/reperfusion-induced cardiomyocyte apoptosis via the PI3K/Akt pathwayApoptosis, 22 (2017), pp. 437-448
- 27NEDD4 E3 ligase: functions and mechanism in human cancerSemin Cancer Biol, 67 (2020), pp. 92-101
- 28Fate tracing of mature hepatocytes in mouse liver homeostasis and regenerationJ Clin Invest, 121 (2011), pp. 4850-4860
- 29Hepatocytic p62 suppresses ductular reaction and tumorigenesis in mouse livers with mTORC1 activation and defective autophagyJ Hepatol, 76 (2022), pp. 639-651
- 30Deficient endoplasmic reticulum-mitochondrial phosphatidylserine transfer causes liver diseaseCell, 177 (2019), pp. 881-895
- 31TOX4, an insulin receptor-independent regulator of hepatic glucose production, is activated in diabetic liverCell Metabol, 34 (2022), pp. 158-170
- 32Expression patterns of hepatic genes involved in lipid metabolism in cows with subclinical or clinical ketosisJ Dairy Sci, 102 (2019), pp. 1725-1735
- 33The MIQE guidelines: minimum information for publication of quantitative real-time PCR experimentsClin Chem, 55 (2009), pp. 611-622
- 34Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT methodMethods, 25 (2001), pp. 402-408
- 35Protocol for primary mouse hepatocyte isolationSTAR Protoc, 1 (2020), Article 100086
- 36Expression patterns of nuclear receptors in parenchymal and non parenchymal mouse liver cells and their modulation in cholestasisBiochimica Et Biochim Biophys Acta Mol Basis Dis, 1863 (2017), pp. 1699-1708
- 37Endoplasmic reticulum stress induces inverse regulations of major functions in portal myofibroblasts during liver fibrosis progressionBiochim Biophys Acta, Mol Basis Dis, 1864 (2018), pp. 3688-3696
- 38Fiji: an open-source platform for biological-image analysisNat Methods, 9 (2012), pp. 676-682
- 39Inhibition of VDAC1 protects against glutamate-induced oxytosis and mitochondrial fragmentation in hippocampal HT22 cellsCell Mol Neurobiol, 39 (2019), pp. 73-85
- 40Oligomerization of the mitochondrial protein voltage-dependent anion channel is coupled to the induction of apoptosisMol Cell Biol, 30 (2010), pp. 5698-5709
- 41Spatial proteogenomics reveals distinct and evolutionarily conserved hepatic macrophage nichesCell, 185 (2022), pp. 379-396
- 42Release of chromatin protein HMGB1 by necrotic cells triggers inflammationNature, 467 (2010), p. 622
- 43Protective effect of high-mobility group box 1 blockade on acute liver failure in ratsShock, 34 (2010), pp. 573-579
- 44p53 up-regulated modulator of apoptosis induction mediates acetaminophen-induced necrosis and liver injury in miceHepatology, 69 (2019), pp. 2164-2179
- 45Protecting mitochondria via inhibiting VDAC1 oligomerization alleviates ferroptosis in acetaminophen-induced acute liver injuryCell Biol Toxicol, 38 (2021), pp. 505-530
- 46Dual roles of p62/SQSTM1 in the injury and recovery phases of acetaminophen-induced liver injury in miceActa Pharm Sin B, 11 (2021), pp. 3791-3805
- 47Acetaminophen hepatotoxicitySemin Liver Dis, 39 (2019), pp. 221-234
- 48Reactive metabolite-induced protein glutathionylation: a potentially novel mechanism underlying acetaminophen hepatotoxicityMol Cell Proteomics, 17 (2018), pp. 2034-2050
- 49A mitochondrial journey through acetaminophen hepatotoxicityFood Chem Toxicol, 140 (2020), Article 111282
- 50Ceramide channels and mitochondrial outer membrane permeabilityJ Bioenerg Biomembr, 49 (2017), pp. 57-64
- 51The role of yeast VDAC genes on the permeability of the mitochondrial outer membraneJ Membr Biol, 161 (1998), pp. 173-181
- 52Mouse VDAC isoforms expressed in yeast: channel properties and their roles in mitochondrial outer membrane permeabilityJ Membr Biol, 170 (1999), pp. 89-102
- 53Mitochondrial VDAC1: a key gatekeeper as potential therapeutic targetFront Physiol, 8 (2017), p. 460
- 54A role for mitochondria in NLRP3 inflammasome activationNature, 469 (2011), pp. 221-225
- 55VDAC oligomers form mitochondrial pores to release mtDNA fragments and promote lupus-like diseaseScience, 366 (2019), pp. 1531-1536
- 56VDAC1 functions in Ca2+ homeostasis and cell life and death in health and diseaseCell Calcium, 69 (2018), pp. 81-100
- 57Proteomic analysis of acetaminophen-induced changes in mitochondrial protein expression using spectral countingChem Res Toxicol, 24 (2011), pp. 549-558
- 58Nedd4 ubiquitylates VDAC2/3 to suppress erastin-induced ferroptosis in melanomaNat Commun, 11 (2020), p. 433
- 59RAS–RAF–MEK-dependent oxidative cell death involving voltage-dependent anion channelsNature, 447 (2007), pp. 864-868
- 60Enhanced expression of the voltage-dependent anion channel 1 (VDAC1) in Alzheimer's disease transgenic mice: an insight into the pathogenic effects of amyloid-betaJ Alzheimers Dis, 23 (2011), pp. 195-206
- 61The role of the mitochondrial protein VDAC1 in inflammatory bowel disease: a potential therapeutic targetMol Ther, 30 (2022), pp. 726-744
- 62VDAC in cancerBiochim Biophys Acta Bioenerg, 1858 (2017), pp. 665-673
- 63c-Jun N-terminal kinase plays a major role in murine acetaminophen hepatotoxicityGastroenterology, 131 (2006), pp. 165-178
- 64Role of JNK translocation to mitochondria leading to inhibition of mitochondria bioenergetics in acetaminophen-induced liver injuryJ Biol Chem, 283 (2008), pp. 13565-13577
- 65Critical role of c-Jun (NH2) terminal kinase in paracetamol-induced acute liver failureGut, 56 (2007), pp. 982-990
- 66Mitochondrial protection by the JNK inhibitor leflunomide rescues mice from acetaminophen-induced liver injuryHepatology, 45 (2007), pp. 412-421
- 67Diffusion of peroxynitrite across erythrocyte membranesProc Natl Acad Sci U S A, 95 (1998), pp. 3566-3571
- 68Acetaminophen hepatotoxicity: a mitochondrial perspectiveAdv Pharmacol, 85 (2019), pp. 195-219
Cited by (8)
The VDAC1 oligomerization regulated by ATP5B leads to the NLRP3 inflammasome activation in the liver cells under PFOS exposure
2024, Ecotoxicology and Environmental SafetyThe role of E3 ubiquitin ligases in bone homeostasis and related diseases
2023, Acta Pharmaceutica Sinica BDMT1 ubiquitination by Nedd4 protects against ferroptosis after intracerebral hemorrhage
2024, CNS Neuroscience and Therapeutics
Peer review under the responsibility of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.
- †
These authors made equal contributions to this work.